Filing Details

Accession Number:
0000921895-19-002393
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-11 13:32:28
Reporting Period:
2019-09-09
Accepted Time:
2019-09-11 13:32:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
835887 Progenics Pharmaceuticals Inc PGNX Pharmaceutical Preparations (2834) 133379479
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1114916 Balaji Venkataraman 1055B Powers Place
Alpharetta GA 30009
No No Yes Yes
1772491 Altiva Management Inc. 1055B Powers Place
Alpharetta GA 30009
No No Yes Yes
1785731 Velan Capital, L.p. 1055 Powers Place, Suite B
Alpharetta GA 30009
No No Yes Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0013 Par Value Acquisiton 2019-09-09 72,023 $4.99 8,011,733 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Footnotes
  1. This Form 4 is filed jointly by Velan Capital, L.P. ("Velan Capital"), Altiva Management Inc. ("Altiva"), and Balaji Venkataraman (collectively, the "Reporting Persons"). The Reporting Persons may be deemed to be members of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Persons disclaim beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose. Further, the Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
  2. Securities owned directly by Velan Capital. Each of Altiva, as the general partner of Velan Capital, and Mr. Venkataraman, as the sole shareholder of Altiva, may be deemed to beneficially own the securities owned directly by Velan Capital.